Dallas, TX -- (ReleaseWire) -- 07/07/2008 -- TwinTrader.com announces the publication of Breakout for MYGN; highlighting public companies on the move and what’s behind the surge.
Investors can view all of the Breakouts and other articles for free by visiting:
“Myriad Genetics Inc., a biotechnology company, engages in the development and marketing of therapeutic and molecular diagnostic products. The company offers molecular diagnostic products comprising BRACAnalysis for assessing a woman's risk for breast and ovarian cancer; COLARIS for determining a person's risk of developing colorectal cancer or uterine cancer; COLARIS AP for assessing a person's risk of developing colon cancer; MELARIS for determining a person's risk of developing melanoma; and THERAGUIDE 5-FU for assessing a patient's risk of developing 5-FU toxicity…
“MYGN’s phase III trial of Flurizan in mild Alzheimer’s disease will likely not succeed, but the company’s other drugs appear to hold a lot of promise for blockbuster future revenues. The bad news appears to have been already discounted as the stock broke through resistance creating a huge short squeeze after J.P Morgan recommended the stock…
“The stock chart clearly indicates a sharp reversal from the March lows of $35. After breaking through the $45 level, the stock tested its support and held. Huge action to the upside was evident on July 1, not only confirming support but also breaking out to new highs, all in one day...”
To read the entire article visit http://www.TwinTrader.com
Join the fastest growing investor community at:
TwinTrader LLC (TT) is not a registered broker-dealer and is not a registered investment advisor. No investor should base their investments decisions upon any act or omission of TT. TT makes no representations or warranties, and none may be relied upon. The purchase and sale of any securities must be made solely with the assistance of a registered broker-dealer and/or investment advisor. TT may, and you should assume that TT does, own shares in the companies profiled on this site. TT intends to sell its shares at times and as otherwise allowed by the securities laws which may negatively affect the performance of the stock price. TT affiliates, officers, directors and employees may have also bought or may buy shares in the companies profiled on this site and may sell, and profit from the sale of, such shares at any time. Except as required by the securities laws, TT will not advise when it or its affiliates, officers, directors and employees intend to sell and will not offer any opinion as to when others should sell. Any recent increase in volume or increase in stock price may be due to trading by TT or its affiliates, officers, directors and employees. TT will not be responsible for any gains or losses due to investing based on any opinions contained on this site. Receipt of the stock profiles, either via e-mail or directly from this site, is not in any way a solicitation or recommendation to buy or sell and should be used for information purposes only. Short-term trading can be extremely risky. As with any investment decision, careful research should be done before making any decision to invest.